Awards & Advancement

CROMSOURCE opens North Carolina office, hires four

Monday, May 2, 2016

CROMSOURCE, an international CRO providing a comprehensive portfolio of services to the pharmaceutical, biotechnology and medical device industries, has appointed four senior executives to its management team. The appointments include Dr. Troy W. McCall as chief operating officer (COO), Debbie Kent as global head of TalentSource staffing solutions, Dr. Kerry Dyson as global head of Clinical Research Division and April McCall as vice president of Commercial Operations. Additionally, CROMSOURCE announced the expansion of its North American presence with the opening of an office in Research Triangle Park in North Carolina.

[Read More]

Valeant names Joseph C. Papa chairman, CEO

Tuesday, April 26, 2016

Valeant Pharmaceuticals International has named Joseph C. Papa to become Valeant’s chairman and chief executive officer. Papa is expected to join Valeant by early May. Papa will join Valeant from Perrigo company, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as chairman and chief executive officer. Papa, who will also join Valeant’s board of directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Papa arrives at Valeant.

[Read More]

Quintiles receives technology security award from CSO Magazine

Monday, April 25, 2016

Quintiles, a provider of biopharmaceutical services, has been named to the 2016 CSO50 by IDG’s CSO magazine. This award recognizes the company’s innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company’s fourth consecutive year receiving the security award.

[Read More]

CRF Health selected to support COPD trials involving 19,000+ patients

Wednesday, April 20, 2016

CRF Health, a global provider of eCOA solutions for the life sciences industry, has announced that its TrialMax platform has been adopted by a developer of therapeutics for respiratory disease conditions to support one of the largest recorded phase III studies into chronic obstructive pulmonary disease (COPD). The trial, involving more than 19,000 patients, will use the TrialMax platform to deliver electronic versions of key COPD instruments, enabling investigators to monitor exacerbations, while making compliance as easy as possible for patients.

[Read More]